Novo Nordisk A/S (NVO): Today's Featured Drugs Winner

Novo Nordisk A/S (NVO) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.6%. By the end of trading, Novo Nordisk A/S rose 77 cents (0.6%) to $141.48 on average volume. Throughout the day, 272,128 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 294,600 shares. The stock ranged in a price between $140.38-$141.55 after having opened the day at $140.81 as compared to the previous trading day's close of $140.71. Other companies within the Drugs industry that increased today were: Rosetta Genomics (ROSG), up 39.2%, Supernus Pharmaceuticals (SUPN), up 8.6%, Skystar Bio-Pharmaceutical Company (SKBI), up 6.8%, and ProPhase Labs (PRPH), up 6.8%.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $82.2 billion and is part of the health care sector. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 25.5 and below the S&P 500 P/E ratio of 17.7. Shares are up 22.1% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Novo Nordisk A/S a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

• You can view the full Novo Nordisk A/S Ratings Report.

On the negative front, CEL-SCI Corporation (CVM), down 18.4%, Savient Pharmaceuticals (SVNT), down 13.4%, AspenBio Pharma (APPY), down 12.5%, and Sequenom (SQNM), down 10.9%, were all losers within the drugs industry with Amgen (AMGN) being today's drugs industry loser.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

For more information on Novo Nordisk A/S click any of the following:

• Novo Nordisk A/S Stock Price

• Novo Nordisk A/S Analyst Ratings

• Novo Nordisk A/S Key Stats & Profile

• Novo Nordisk A/S Earnings

• Novo Nordisk A/S Ratio Comparison

• Novo Nordisk A/S Growth Rates

• Novo Nordisk A/S Balance Sheet

• Novo Nordisk A/S Cash Flow

• Novo Nordisk A/S Income Statement